Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNGT70
|
|||
| Drug Name |
CRD-740
|
|||
| Indication | Heart failure [ICD-11: BD10-BD13] | Phase 2 | [1] | |
| Company |
Cardurion Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 9 (PDE9) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Purine metabolism | |||
| Pathway Interaction Database | Regulation of Androgen receptor activity | |||
| Reactome | cGMP effects | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05409183) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 in Subjects With Chronic Heart Failure (CARDINAL-HF). U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.